09 Jun Orphan Drug Regulatory Incentives for Biopharmaceutical Innovation
Posted at 15:05h in Conferences 0 Comments
Next week, the 7th Conference of the American Society of Health Economics (ASHEcon) at Emory University (Atlanta, USA) between June 10th and June 13th, 2018. During a session on Incentives for Biopharmaceutical Innovation, we will discuss with US scholars, Kirk W. Kerr (from FDA), Richard Manning and Frederic Selck (from Bates White) how does intellectual property protection influence biotechnology investment decisions? I will discuss with colleagues if the Orphan Drug (OD) market exclusivity (ME) extend or not the drug patent monopoly.